Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN2477 placebo-controlled phase 2 study in fibrodysplasia ossificans progressiva
2016-005035-33Phase 2Unknown
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of garetosmab in fibrodysplasia ossificans progressiva (FOP), sponsored by Regeneron Pharmaceuticals. Status: unknown.
02
Drugs
garetosmab
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on 2016-005035-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005035-33.